A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

Sponsor

AstraZeneca (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT04541433

Collaborator

(none)

Enrollment

Locations

Arm

Anticipated Duration (Months)

3.3

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AZD9833 in Japanese women with endocrineresistant ER+ HER2- breast cancer that is not amenable to treatment with curative intent. This study consists of 2 cohorts, Cohort1 and Cohort2. In cohort 1 (for tolerability evaluation), a minimum of 3, or up to 6, evaluable Japanese patients with ER+ HER2- breast cancer will be enrolled. In cohort 2 (for exploratory research), at least 6 to maximum 12 evaluable Japanese patients with ER+ HER2- breast cancer will be enrolled.

Condition or Disease	Intervention/Treatment	Phase
ER+ HER2- Advanced Breast Cancer	Drug: AZD9833	Phase 1

Detailed Description

Objectives:

Primary objective:

To investigate the safety and tolerability of AZD9833 in Japanese women with ER+ HER2- advanced breast cancer

Secondary objective:

To assess the anti-tumor activity and efficacy of AZD9833

Exploratory objectives:

To investigate AZD9833 activity in tumor cells

Overall design:

For cohort 2, if paired biopsy after administration of the study drug becomes inoperable during administration of the study drug, additional subjects can be added to obtain an evaluable biopsy sample.

In cohort 2 (for exploratory research), eligible patients will receive AZD9833 once daily and at least 6 to maximum 12 patients will be enrolled. In cohort 2, paired biopsy sample will be collected from at least 6 and maximum 12 patients. If paired biopsy after administration of the study drug becomes inoperable during administration of the study drug, additional subjects can be added to obtain an evaluable biopsy sample.

Number of Subjects:

Maximum 18 evaluable subjects will be enrolled in this study.

Study Design

Study Type:

Interventional

Actual Enrollment :

10 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti- Tumor Activity of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

Actual Study Start Date :

Sep 29, 2020

Anticipated Primary Completion Date :

Nov 30, 2022

Anticipated Study Completion Date :

Nov 30, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: AZD9833 monotherapy Dose escalation of AZD9833 monotherapy for patients with ER+ HER2- advanced breast cancer	Drug: AZD9833 AZD9833 taken orally

Arm

Intervention/Treatment

Experimental: AZD9833 monotherapy

Dose escalation of AZD9833 monotherapy for patients with ER+ HER2- advanced breast cancer

Drug: AZD9833

AZD9833 taken orally

Outcome Measures

Primary Outcome Measures

The number of subjects with dose-limiting toxicity, as defined in the protocol. [From the first dose of study treatment up to and including Cycle1 Day28.]
Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optimal therapeutic intervention, meets protocol-defined criteria.
The number of subjects with treatment-related adverse events as assessed by CTCAE v5.0. [Minimum observation period 28 days on treatment or 28 days with at least 75% of the required dose and will continue until the subject is off the study (approximately 1 year).]
Safety data will be assessed as the number of subjects with treatment-related adverse events.

Secondary Outcome Measures

Objective Response Rate [At Cycle3 Day1, Cycle5 Day1, Cycle7 Day1 (each cycle is 28 days) and every 12 weeks until the end of the study (approximately 1 year).]
Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
Duration of Response [At Cycle3 Day1, Cycle5 Day1, Cycle7 Day1 (each cycle is 28 days) and every 12 weeks until the end of the study (approximately 1 year).]
Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
Clinical benefit rate at 24 weeks [Up to 24 weeks]
Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
Percentage Change in Tumour Size [At Cycle3 Day1, Cycle5 Day1, Cycle7 Day1 (each cycle is 28 days) and every 12 weeks until the end of the study (approximately 1 year).]
Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
Progression Free Survival [Up to objective disease progression or death (approximately 1 year).]
Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
Maximum Observed Plasma Concentration (Cmax) of AZD9833 [At predefined intervals throughout the AZD9833 treatment period (approximately 12 weeks )]
Blood samples will be collected to assess plasma concentrations of AZD9833 at a series of timepoints to derive Cmax
Time to observed Cmax (Tmax) for AZD9833 [At predefined intervals throughout the AZD9833 treatment period (approximately 12 weeks )]
Blood samples will be collected to assess plasma concentrations of AZD9833 at a series of timepoints to derive Tmax

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years to 130 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Major Inclusion Criteria:

Signed written informed consent.
= 20 years.
Any menopausal status:

Pre and Post menopausal defined according to standard criteria in the protocol.

Histological or cytological confirmation of adenocarcinoma of the breast.
Documented positive estrogen receptor status of primary or metastatic tumor tissue, according to the local laboratory parameters. HER-2 negative.
Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to starting IMP.
Prior chemotherapy, endocrine therapy and other therapy in the advanced setting is restricted as follows:
No more than 2 lines of chemotherapy for advanced disease.
Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.
There is no limit on the number of lines of prior endocrine therapies.
Prior treatment with CDK4/6 inhibitors is permitted.
At least one lesion (measurable and/or non-measurable, as per RECIST 1.1) that can be accurately assessed at baseline and is suitable for repeated assessment by computed tomography (CT), magnetic resonance imaging (MRI), or plain X-ray; or clinical examination.
Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0 to 1

Major Exclusion Criteria:

Intervention with any of the following:
Any cytotoxic chemotherapy, investigational agents, or other anti-cancer drugs for the treatment of advanced breast cancer from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
Medications or herbal supplements known to be strong inhibitors/inducers of cytochrome P450 (CYP) 3A4/5 sensitive CYP2B6 substrates and drugs which are substrates of CYP2C9 and/or CYP2C19.
Drugs that are known to prolong QT and have a known risk of Torsades de Pointes.
Radiotherapy with a limited field of radiation for palliation within one week of the first dose of IMP, radiotherapy to more than 30% of the bone marrow or a wide field of radiation within 4 weeks of the first dose of IMP.
Major surgical procedure or significant traumatic injury.
Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting IMP.
Presence of life-threatening metastatic visceral disease.
Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses.
Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9833.
History of another primary malignancy.
Male subjects are excluded from this study.
History of hypersensitivity to active or inactive excipients of AZD9833.
The following cardiovascular criteria: QTcF >470 ms, resting heart rate <45 bpm, clinically significant abnormalities of resting electrocardiogram, uncontrolled hypertension, symptomatic hypotension, factors that increase the risk for QTc prolongation, left ventricular ejection fraction <50%.
Inadequate bone marrow reserve or organ function
Involvement in the planning and conduct of the study.
Judgment by the investigator that the patient should not participate in the study.